These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 3279

  • 21. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J, Nidhinandana S, Srisuwananukorn S, Laptikultham S, Pisarnpong A, Chankrachang S, Bundhukul A.
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.
    Stocchi F, Ruggieri S, Carta A, Ryatt J, Quinn N, Jenner P, Marsden CD, Agnoli A.
    Mov Disord; 1992 Nov; 7(3):249-56. PubMed ID: 1620143
    [Abstract] [Full Text] [Related]

  • 28. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P, Parkinson-Control Study Group.
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
    Kulisevsky J, López-Villegas D, García-Sánchez C, Barbanoj M, Gironell A, Pascual-Sedano B.
    Clin Neuropharmacol; 1998 Apr; 21(6):358-62. PubMed ID: 9844794
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
    Mizuno Y, Yanagisawa N, Kuno S, Yamamoto M, Hasegawa K, Origasa H, Kowa H, Japanese Pramipexole Study Group.
    Mov Disord; 2003 Oct; 18(10):1149-56. PubMed ID: 14534919
    [Abstract] [Full Text] [Related]

  • 35. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 36. Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man.
    Barbeau A.
    Lancet; 1975 Oct 11; 2(7937):683-4. PubMed ID: 52054
    [Abstract] [Full Text] [Related]

  • 37. Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy.
    Caraceni T, Parati EA, Girotti F, Celano I, Frigerio C, Cocchi D, Müller EE.
    Psychopharmacology (Berl); 1979 Jun 21; 63(3):217-22. PubMed ID: 39308
    [Abstract] [Full Text] [Related]

  • 38. [Infusion therapy with mif (melanocyte inhibiting factor) in Parkinson's disease (author's transl)].
    Gerstenbrand F, Binder H, Kozma C, Pusch ST, Reisner Th.
    Wien Klin Wochenschr; 1975 Dec 26; 87(24):822-3. PubMed ID: 5815
    [Abstract] [Full Text] [Related]

  • 39. Effects of the neuropeptide PLG (L-prolyl-leucyl-glycinamide) on writing pressure and speed in healthy subjects.
    Steinwachs KC, Fehm HL.
    Pharmacopsychiatry; 1988 Nov 26; 21(6):459-60. PubMed ID: 3244794
    [Abstract] [Full Text] [Related]

  • 40. Stapling Amantadine to Melanostatin Neuropeptide: Discovery of Potent Positive Allosteric Modulators of the D2 Receptors.
    Silva-Reis SC, Correia XC, Costa-Almeida HF, Pires-Lima BL, Maronde D, Costa VM, García-Mera X, Cruz L, Brea J, Loza MI, Rodríguez-Borges JE, Sampaio-Dias IE.
    ACS Med Chem Lett; 2023 Dec 14; 14(12):1656-1663. PubMed ID: 38116429
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.